Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
The current price of TLSA.BOATS is $1.3 USD — it has increased by +0% in the past 24 hours. Watch Tiziana Life Sciences stock price performance more closely on the chart.
What is Tiziana Life Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tiziana Life Sciences stocks are traded under the ticker TLSA.BOATS.
When is the next Tiziana Life Sciences earnings date?▼
Tiziana Life Sciences is going to release the next earnings report on June 18, 2026.
How many employees does Tiziana Life Sciences have?▼
As of April 01, 2026, the company has 9 employees.
In which sector is Tiziana Life Sciences located?▼
Tiziana Life Sciences operates in the Health Care sector.
When did Tiziana Life Sciences complete a stock split?▼
Tiziana Life Sciences has not had any recent stock splits.
Where is Tiziana Life Sciences headquartered?▼
Tiziana Life Sciences is headquartered in London, GB.